Bayer prescription drug Beijing factory is the world's largest prescription drug packaging base
release date: Source: Beijing News Editor: Arnold browse times: 1950 copyright and disclaimer
core tip: on November 18, the two-year comprehensive expansion project of Bayer prescription drug Beijing factory was officially opened, and the Beijing factory has also become Bayer's largest prescription drug packaging base in the world. It is understood that the opening of this comprehensive expansion project will ensure the stable supply of Bayer prescription drugs
[China Packaging News] on November 18, the two-year comprehensive expansion project of Bayer prescription drug factory in Beijing was officially launched, and the Beijing factory has also become Bayer's largest prescription drug packaging base in the world. It is understood that the opening of this comprehensive expansion project will ensure the stable supply of Bayer prescription drugs. The launch of the project also confirmed Bayer's confidence in Greater China, the largest single market in Asia. Johannes dietsch, member of the board of directors and chief financial officer of Bayer Group, said that this move has effectively enhanced China's strategic position in Bayer's global prescription drug supply system, and once again confirmed Bayer's solid confidence and commitment to its largest single market in AsiaIn addition, the production capacity of Bayer's Beijing factory for prescription drugs has increased significantly.
on November 18, the comprehensive expansion project of Bayer's Beijing factory for prescription drugs was officially opened, which also marks that the factory has become Bayer's largest prescription drug packaging base in the world. In 2014, Bayer spent about 100 million euros on a large-scale increase in the production capacity of its Beijing factory for prescription drugs. The project lasted two years
Bayer prescription drug Division currently has factories in Beijing and Guangzhou. The opening of the comprehensive expansion project of Beijing factory will ensure the stable supply of Bayer prescription drug products. This comprehensive expansion project includes high-speed packaging production lines, fully automated logistics systems, etc. with fully automated logistics systems and continuous optimization of processes, the overall production capacity has been doubled without increasing the storage area
after the project is launched, the increase in the production capacity of Bayer's prescription drug factory in Beijing will ensure the stable supply of Baitangping, baixintong, aspirin enteric coated tablets and other drugs in China. Professor wolfram Carius, executive vice president of Bayer's prescription drug product supply, said that Bayer has long maintained the industry benchmark position in the field of drug supply in China and will continue to introduce the world's top production technology and quality control standards into the drug supply system in China. The Beijing plant will become an important asset in Bayer's global supply network
since Bayer first entered the Chinese market in 1882, the Greater China region (Chinese Mainland, Hong Kong and Taiwan) has now become Bayer's largest single market in Asia. In 2015, Bayer's sales in this region exceeded 4.5 billion euros, and local production accounts for an increasing proportion of sales in Greater China. Johannes dietsch, a member of Bayer Group's board of directors and chief financial officer, said: "this move (expansion project) has effectively enhanced China's strategic position in Bayer's global prescription drug supply system, and once again confirmed Bayer's firm confidence and commitment to its largest single market in Asia."
Bayer continues to provide professional training for grassroots doctors
Chinese society has entered a period of high incidence and high burden of chronic diseases, which is characterized by "a large number of patients, high medical costs, long illness time, and high service demand". According to statistics, there are more than 260million patients with three chronic diseases that have been diagnosed in China; Among citizens over 18 years old, 25.2% suffer from hypertension and 9.7% from diabetes. At the same time, the proportion of deaths caused by chronic diseases in China's total deaths has risen to 85%
in 2013, the "2525 plan" issued by the World Health Organization clearly stated that premature deaths caused by chronic diseases should be reduced by 25% in countries around the world by 2025. The outline of the "healthy China 2030" plan also lists chronic disease management as a strategic task in the next 15 years
at the opening ceremony of the project on the same day, experts and scholars in the field of health at home and abroad and relevant principals of Bayer also discussed the topic of "focusing on chronic disease management and building a healthy China together". Xing Xiaoping, vice president of the endocrinologist branch of the Chinese Medical Association and director of the Endocrinology Department of Peking Union Medical College Hospital, believes that in response to the increasingly severe challenge of chronic diseases, different sample sizes are often given for different materials in the same standard. Disease prevention and control should shift from treatment to management. We must adhere to the whole process management concept of prevention first and prevention and control, so as to help more patients benefit from early detection, early diagnosis The "four early" actions of early treatment and early compliance will comprehensively reduce the incidence rate, mortality and disability rate of chronic diseases
Bayer has been committed to helping China improve the level of primary medical care and improve the efficiency and quality of the medical system for many years. Through the "entering the west" project, Bayer continues to provide comprehensive professional training in diagnosis and treatment technology and hospital management for primary doctors and hospital managers in the central and Western regions. From 2007 to 2016, the project of "entering the west" has been extended to 26 provinces across the country, and 233 training courses have been carried out, with a total of more than 30000 health personnel trained